Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-60

phase 3... stand alone trial has always been on the cards.
accelerated approval has always been on the cards.

neither have changed except we are moving forward without dilution nor partners (currently) to share the spoils with. that's all we know at this moment in time. Directions change to the best path forward at the time depending on the set of circumstances. To get upset about this company not bringing a drug to market ten years ago plays into the biotech success statistics that are easily found and constantly proven. I see this as no different, except that our odds of winning now, a this point are much higher.